JP2007523905A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523905A5 JP2007523905A5 JP2006553657A JP2006553657A JP2007523905A5 JP 2007523905 A5 JP2007523905 A5 JP 2007523905A5 JP 2006553657 A JP2006553657 A JP 2006553657A JP 2006553657 A JP2006553657 A JP 2006553657A JP 2007523905 A5 JP2007523905 A5 JP 2007523905A5
- Authority
- JP
- Japan
- Prior art keywords
- oxy
- methylethyl
- thiazol
- phenoxy
- ylbenzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 25
- -1 2-fluoro-4-methanesulfonylphenoxy Chemical group 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 17
- 239000012453 solvate Substances 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 239000000651 prodrug Substances 0.000 claims 15
- 229940002612 prodrug Drugs 0.000 claims 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 12
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 238000006243 chemical reaction Methods 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 238000010640 amide synthesis reaction Methods 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000010931 ester hydrolysis Methods 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002524 organometallic group Chemical group 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- ZNRKDXPBZXBAKF-UHFFFAOYSA-N 3-(4-methylsulfonylphenoxy)-n-(4-methyl-1,3-thiazol-2-yl)-5-propan-2-yloxybenzamide Chemical compound C=1C(C(=O)NC=2SC=C(C)N=2)=CC(OC(C)C)=CC=1OC1=CC=C(S(C)(=O)=O)C=C1 ZNRKDXPBZXBAKF-UHFFFAOYSA-N 0.000 claims 1
- QIVKMHJFESNBHW-UHFFFAOYSA-N 3-[4-(4-methylpiperazine-1-carbonyl)phenoxy]-5-propan-2-yloxy-n-(1,3-thiazol-2-yl)benzamide Chemical compound C=1C(C(=O)NC=2SC=CN=2)=CC(OC(C)C)=CC=1OC(C=C1)=CC=C1C(=O)N1CCN(C)CC1 QIVKMHJFESNBHW-UHFFFAOYSA-N 0.000 claims 1
- DVJBUMFRVQCSPD-UHFFFAOYSA-N 3-[4-(azetidine-1-carbonyl)-2-chlorophenoxy]-n-(1-methylpyrazol-3-yl)-5-propan-2-yloxybenzamide Chemical compound C=1C(C(=O)NC2=NN(C)C=C2)=CC(OC(C)C)=CC=1OC(C(=C1)Cl)=CC=C1C(=O)N1CCC1 DVJBUMFRVQCSPD-UHFFFAOYSA-N 0.000 claims 1
- PZVZSRFJTCPSGM-UHFFFAOYSA-N 3-[4-(azetidine-1-carbonyl)-2-fluorophenoxy]-n-(1-methylpyrazol-3-yl)-5-propan-2-yloxybenzamide Chemical compound C=1C(C(=O)NC2=NN(C)C=C2)=CC(OC(C)C)=CC=1OC(C(=C1)F)=CC=C1C(=O)N1CCC1 PZVZSRFJTCPSGM-UHFFFAOYSA-N 0.000 claims 1
- BAOJTMHVZPBUMK-UHFFFAOYSA-N 3-[4-(azetidine-1-carbonyl)phenoxy]-5-propan-2-yloxy-n-(1,3-thiazol-2-yl)benzamide Chemical compound C=1C(C(=O)NC=2SC=CN=2)=CC(OC(C)C)=CC=1OC(C=C1)=CC=C1C(=O)N1CCC1 BAOJTMHVZPBUMK-UHFFFAOYSA-N 0.000 claims 1
- OXNVCIZHPJWTGC-UHFFFAOYSA-N 3-[4-(azetidine-1-carbonyl)phenoxy]-n-(1-methylpyrazol-3-yl)-5-propan-2-yloxybenzamide Chemical compound C=1C(C(=O)NC2=NN(C)C=C2)=CC(OC(C)C)=CC=1OC(C=C1)=CC=C1C(=O)N1CCC1 OXNVCIZHPJWTGC-UHFFFAOYSA-N 0.000 claims 1
- IJMPQUPDCRIEHU-UHFFFAOYSA-N 3-[4-[methyl-(1-methylpiperidin-4-yl)carbamoyl]phenoxy]-n-(3-methyl-1,2,4-thiadiazol-5-yl)-5-propan-2-yloxybenzamide Chemical compound C=1C(C(=O)NC=2SN=C(C)N=2)=CC(OC(C)C)=CC=1OC(C=C1)=CC=C1C(=O)N(C)C1CCN(C)CC1 IJMPQUPDCRIEHU-UHFFFAOYSA-N 0.000 claims 1
- RVHJWYOXNLKTHV-UHFFFAOYSA-N 3-chloro-n,n-dimethyl-4-[3-propan-2-yloxy-5-(1,3-thiazol-2-ylcarbamoyl)phenoxy]benzamide Chemical compound C=1C(C(=O)NC=2SC=CN=2)=CC(OC(C)C)=CC=1OC1=CC=C(C(=O)N(C)C)C=C1Cl RVHJWYOXNLKTHV-UHFFFAOYSA-N 0.000 claims 1
- NJWOHKGHTDMDPZ-UHFFFAOYSA-N 3-chloro-n-(2-methoxyethyl)-4-[3-propan-2-yloxy-5-(1,3-thiazol-2-ylcarbamoyl)phenoxy]benzamide Chemical compound ClC1=CC(C(=O)NCCOC)=CC=C1OC1=CC(OC(C)C)=CC(C(=O)NC=2SC=CN=2)=C1 NJWOHKGHTDMDPZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- VFNLSKCEZGBUHF-UHFFFAOYSA-N n-[4-[(dimethylamino)methyl]-1,3-thiazol-2-yl]-3-(4-methylsulfonylphenoxy)-5-propan-2-yloxybenzamide Chemical compound C=1C(C(=O)NC=2SC=C(CN(C)C)N=2)=CC(OC(C)C)=CC=1OC1=CC=C(S(C)(=O)=O)C=C1 VFNLSKCEZGBUHF-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 C*NC(c1cc(I)cc(OC(C)I)c1)=O Chemical compound C*NC(c1cc(I)cc(OC(C)I)c1)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0403595A GB0403595D0 (en) | 2004-02-18 | 2004-02-18 | Compounds |
| GB0413388A GB0413388D0 (en) | 2004-06-16 | 2004-06-16 | Compounds |
| PCT/GB2005/000562 WO2005080360A1 (en) | 2004-02-18 | 2005-02-15 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007523905A JP2007523905A (ja) | 2007-08-23 |
| JP2007523905A5 true JP2007523905A5 (enExample) | 2008-12-18 |
Family
ID=34889135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553657A Withdrawn JP2007523905A (ja) | 2004-02-18 | 2005-02-15 | 化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080312207A1 (enExample) |
| EP (1) | EP1718625A1 (enExample) |
| JP (1) | JP2007523905A (enExample) |
| KR (1) | KR20070007104A (enExample) |
| AR (1) | AR048495A1 (enExample) |
| AU (1) | AU2005214137B2 (enExample) |
| BR (1) | BRPI0507734A (enExample) |
| CA (1) | CA2554686A1 (enExample) |
| IL (1) | IL177217A0 (enExample) |
| NO (1) | NO20064008L (enExample) |
| TW (1) | TW200604186A (enExample) |
| UY (1) | UY28755A1 (enExample) |
| WO (1) | WO2005080360A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| BRPI0407283A (pt) | 2003-02-13 | 2006-01-31 | Banyu Pharma Co Ltd | Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade |
| WO2004076420A1 (ja) | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | ヘテロアリールカルバモイルベンゼン誘導体 |
| EP2048137A1 (en) * | 2004-02-18 | 2009-04-15 | AstraZeneca AB | Benzamide derivatives and their use as glucokinase activating agents. |
| TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| KR20110084339A (ko) | 2005-07-09 | 2011-07-21 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체 |
| CA2621406A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Pparactive compounds |
| NZ566877A (en) | 2005-09-29 | 2010-05-28 | Sanofi Aventis | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| JP2009544648A (ja) | 2006-07-24 | 2009-12-17 | エフ．ホフマン−ラ ロシュ アーゲー | グルコキナーゼ活性化剤としてのピラゾール類 |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| TW200825060A (en) * | 2006-10-26 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| MX2009006729A (es) * | 2006-12-21 | 2009-08-07 | Astrazeneca Ab | Nuevo compuesto cristalino util como activador de glk. |
| DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5457358B2 (ja) | 2007-10-09 | 2014-04-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコキナーゼアクチベーターとしてのｎ−（ピラゾール−３−イル）−ベンズアミド誘導体 |
| EP2245025A1 (en) * | 2008-02-27 | 2010-11-03 | Merck Patent GmbH | Carboxamide-heteroaryl derivatives for the treatment of diabetes |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| MX2011001333A (es) | 2008-08-04 | 2011-03-15 | Astrazeneca Ab | Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad. |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| GB0902406D0 (en) | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| AR076220A1 (es) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivados de pirazol [4,5 - e] pirimidina |
| WO2010116176A1 (en) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity |
| US8450494B2 (en) | 2009-06-22 | 2013-05-28 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (GK) activators |
| EP2459554B1 (en) | 2009-07-31 | 2013-09-18 | Cadila Healthcare Limited | Substituted benzamide derivatives as glucokinase (gk) activators |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| BR112012016025A2 (pt) * | 2009-12-11 | 2018-11-06 | Astellas Pharma Inc. | composto de benzamida |
| US8222416B2 (en) | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| BR112021002207A2 (pt) | 2018-08-10 | 2021-05-04 | Diapin Therapeutics, Llc | tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios |
| JP2022553490A (ja) * | 2019-10-11 | 2022-12-23 | ナンヤン・テクノロジカル・ユニバーシティー | 分解性高分子材料 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2750393A (en) * | 1954-12-01 | 1956-06-12 | Sterling Drug Inc | Iodinated 5-henzamidotetrazoles and preparation thereof |
| US2967194A (en) * | 1958-05-15 | 1961-01-03 | Pennsalt Chemicals Corp | 4-trifluoromethylsalicylamides |
| GB1400540A (en) * | 1972-12-06 | 1975-07-16 | Smith Kline French Lab | Salicylamides and compositions thereof |
| US4009174A (en) * | 1972-12-08 | 1977-02-22 | The Boots Company Limited | Esters of substituted nicotinic acids |
| GB1437800A (en) * | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
| GB1561350A (en) * | 1976-11-05 | 1980-02-20 | May & Baker Ltd | Benzamide derivatives |
| FR2344284A1 (fr) * | 1976-03-17 | 1977-10-14 | Cerm Cent Europ Rech Mauvernay | Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs |
| US4474792A (en) * | 1979-06-18 | 1984-10-02 | Riker Laboratories, Inc. | N-Tetrazolyl benzamides and anti-allergic use thereof |
| FR2493848B2 (fr) * | 1980-11-07 | 1986-05-16 | Delalande Sa | Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique |
| JPS59139357A (ja) * | 1983-01-28 | 1984-08-10 | Torii Yakuhin Kk | アミジン誘導体 |
| CA1327358C (en) * | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
| US5466715A (en) * | 1991-12-31 | 1995-11-14 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
| US5258407A (en) * | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
| US5273986A (en) * | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
| US5661153A (en) * | 1994-07-19 | 1997-08-26 | Japan Energy Corporation | 1-arylpyrimidine derivatives and pharmaceutical use thereof |
| US5510478A (en) * | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| US5672750A (en) * | 1994-12-16 | 1997-09-30 | Eastman Chemical Company | Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride |
| US5849735A (en) * | 1995-01-17 | 1998-12-15 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5712270A (en) * | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| AUPO395396A0 (en) * | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| FR2757852B1 (fr) * | 1996-12-31 | 1999-02-19 | Cird Galderma | Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations |
| WO1999000372A1 (fr) * | 1997-06-27 | 1999-01-07 | Fujisawa Pharmaceutical Co., Ltd. | Sulfamides et leur utilisation medicale |
| WO1999000359A1 (en) * | 1997-06-27 | 1999-01-07 | Fujisawa Pharmaceutical Co., Ltd. | Aromatic ring derivatives |
| US6613942B1 (en) * | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| AU759255B2 (en) * | 1998-01-29 | 2003-04-10 | Amgen, Inc. | PPAR-gamma modulators |
| DE19816780A1 (de) * | 1998-04-16 | 1999-10-21 | Bayer Ag | Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide |
| GB9811969D0 (en) * | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
| US6197798B1 (en) * | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
| RU2242469C2 (ru) * | 1999-03-29 | 2004-12-20 | Ф.Хоффманн-Ля Рош Аг | Активаторы глюкокиназы |
| US6320050B1 (en) * | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| US6610846B1 (en) * | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| AU1917201A (en) * | 1999-11-18 | 2001-05-30 | Centaur Pharmaceuticals, Inc. | Amide therapeutics and methods for treating inflammatory bowel disease |
| WO2001064642A2 (en) * | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US6534651B2 (en) * | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| EP1282612B1 (en) * | 2000-05-03 | 2004-12-29 | F. Hoffmann-La Roche Ag | Alkynyl phenyl heteroaromatic glucokinase activators |
| DE60118774T2 (de) * | 2000-11-22 | 2007-03-15 | Astellas Pharma Inc. | Substituierte phenolderivate und deren salze als hemmstoffe von koagulations faktor x |
| EP1341774B1 (en) * | 2000-12-06 | 2006-02-01 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
| CN1289072C (zh) * | 2000-12-22 | 2006-12-13 | 石原产业株式会社 | 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂 |
| SE0102299D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| MXPA04001253A (es) * | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
| SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| WO2004007472A1 (ja) * | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ｃｃｒ４アンタゴニストおよびその医薬用途 |
| GB0226931D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| WO2004076420A1 (ja) * | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | ヘテロアリールカルバモイルベンゼン誘導体 |
| WO2005048953A2 (en) * | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Amide derivatives as kinase modulators |
-
2005
- 2005-02-15 JP JP2006553657A patent/JP2007523905A/ja not_active Withdrawn
- 2005-02-15 WO PCT/GB2005/000562 patent/WO2005080360A1/en not_active Ceased
- 2005-02-15 CA CA002554686A patent/CA2554686A1/en not_active Abandoned
- 2005-02-15 KR KR1020067019160A patent/KR20070007104A/ko not_active Withdrawn
- 2005-02-15 EP EP05708370A patent/EP1718625A1/en not_active Withdrawn
- 2005-02-15 BR BRPI0507734-6A patent/BRPI0507734A/pt not_active IP Right Cessation
- 2005-02-15 AU AU2005214137A patent/AU2005214137B2/en not_active Ceased
- 2005-02-15 US US10/588,315 patent/US20080312207A1/en not_active Abandoned
- 2005-02-16 AR ARP050100541A patent/AR048495A1/es not_active Application Discontinuation
- 2005-02-17 UY UY28755A patent/UY28755A1/es not_active Application Discontinuation
- 2005-02-17 TW TW094104678A patent/TW200604186A/zh unknown
-
2006
- 2006-08-01 IL IL177217A patent/IL177217A0/en unknown
- 2006-09-06 NO NO20064008A patent/NO20064008L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007523142A5 (enExample) | ||
| JP2008501673A5 (enExample) | ||
| RU2392275C2 (ru) | Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов | |
| CN100577163C (zh) | 影响葡糖激酶的化合物 | |
| AU2005214137B2 (en) | Compounds | |
| TWI222447B (en) | 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents | |
| JP4860606B2 (ja) | 糖尿病の処置にｇｌｋアクチベーターとして用いるためのヘテロアリールベンズアミド誘導体 | |
| JP2014511869A5 (enExample) | ||
| CA2630269A1 (en) | Inhibitors of diacyglycerol acyltransferase (dgat) | |
| EP1794156A2 (en) | Trombopoietin receptor agonists | |
| JP2010533158A5 (enExample) | ||
| JP2008517945A5 (enExample) | ||
| RU2008117170A (ru) | Пиримидинамидные соединения как ингибиторы pgds | |
| CA2614746A1 (en) | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes | |
| RU2007100136A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| WO2007123269A1 (ja) | アゾールカルボキサミド誘導体 | |
| JP2015517580A5 (enExample) | ||
| JP2010540462A5 (enExample) | ||
| JP2013506637A5 (enExample) | ||
| JP2014523400A5 (enExample) | ||
| JP2014513122A5 (enExample) | ||
| JP2005525371A5 (enExample) | ||
| RU2016129018A (ru) | Производные оксиндола, их получение и терапевтическое применение при лечении заболеваний, связанных с амрк | |
| US8637550B2 (en) | Heteroaryl diamide compounds useful as MMP-13 inhibitors | |
| HRP20100592T1 (hr) | Amidni derivati koji nose ciklopropilaminokarbonilni supstituent korisni kao inhibitori citokina |